PROGRAM Plus
PROGRAM Plus
Authorised
- Milbemycin oxime
- Lufenuron
Product identification
Medicine name:
PROGRAM Plus
INTERCEPTOR PLUS compresse rivestite da 11,5 mg/230 mg per cani
Active substance:
- Milbemycin oxime
- Lufenuron
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Milbemycin oxime11.50/milligram(s)1.00Tablet
-
Lufenuron230.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Film-coated tablet
Withdrawal period by route of administration:
-
Oral use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP54AB51
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Italy
Package description:
- Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton
- Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Elanco France S.A.S
Responsible authority:
- Ministry Of Health
Authorisation number:
- 102569
Date of authorisation status change:
Reference member state:
-
Italy
Procedure number:
- IT/V/0106/003
Concerned member states:
-
Austria
-
Germany
-
Portugal
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 14/02/2022
Combined File of all Documents
This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 14/02/2022
How useful was this page?:
